$SciSparc (SPRC.US)$ $N2OFF (NITO.US)$ SciSparc Signs Definitive Agreement to Sell MitoCareX to N2Off
Dow Jones· 3 mins ago

$SciSparc (SPRC.US)$
SciSparc's Strategic Exit: How Its MitoCareX Sale Could Deliver $2.3M+ in Value

$SciSparc (SPRC.US)$
$N2OFF (NITO.US)$
conflict of interest sounds like FUD
cough cough 🌽

$SciSparc (SPRC.US)$
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
Thursday, 27th February at 8:45 am
TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement...

$N2OFF (NITO.US)$ $SciSparc (SPRC.US)$
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers
Wednesday, 26th February at 9:29 am
Neve Yarak, Israel, Feb. 26, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) ("N2OFF" and the "Company"), a clean tech company engaged in sustainable solutions for solar energy, energy battery storage and innovation for agri- tech, announced today that it has entered a definitive agree...

$SciSparc (SPRC.US)$
bought the dip

$SciSparc (SPRC.US)$
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
Tuesday, 18th February at 7:17 am
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous...